JR
Therapeutic Areas
Supernus Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Qelbree® (viloxazine ER) | Attention-Deficit/Hyperactivity Disorder (ADHD) | Approved/Commercial |
| Trokendi XR® | Epilepsy, Migraine Prevention | Approved/Commercial |
| Oxtellar XR® | Epilepsy | Approved/Commercial |
| SPN-820/821 | Treatment-Resistant Depression (TRD) | Phase 2 |
| SPN-817 | Severe Epilepsy | Phase 2 |
| Adderall XR® | ADHD | Approved/Commercial |
| Intuniv® | ADHD | Approved/Commercial |
| Mydayis® | ADHD | Approved/Commercial |
Leadership Team at Supernus Pharmaceuticals
JA
Jack A. Khattar
President and Chief Executive Officer, Director
TC
Timothy C. Dec
Senior Vice President, Chief Financial Officer
KT
Kevin T. Anderson, Esq.
Compliance Officer
RL
Rebecca Lannan
Employee (Featured in About Us video)
CT
Chad Tasker
Employee (Featured in About Us video)
SM
Sarah Munoz
Employee (Featured in About Us video)
BR
Bryan Roecklein
Employee (Featured in About Us video)
KT
Konnie Taylor
Employee (Featured in About Us video)
RT
Roy Thomas
Employee (Featured in About Us video)
EA
Erin Agustinus
Employee (Featured in About Us video)